The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
Abstract
Purpose: Previous studies have highlighted the importance of an appropriate human epidermal growth factor receptor 2 (HER2) evaluation for the proper identification of patients eligible for treatment with anti-HER2 targeted therapies. Today, the relationship remains unclear between the level of HER2 amplification and the outcome of HER2-positive gastric cancer treated with first-line chemotherapy with trastuzumab. The aim of this study was to determine whether the level of HER2 gene amplification determined by the HER2/CEP17 ratio and HER2 gene copy number could significantly predict some benefit in overall survival and response to therapy in advanced gastric cancer treated with trastuzumab-based chemotherapy. Patients and Methods: Ninety patients with metastatic gastric cancer treated with first-line trastuzumab-based chemotherapy were studied. The optimal cutoff values for HER2/CEP17 ratio and HER2 gene copy number (GCN) for discriminating positive results in terms of response and prolonged survival were determined using receiver operating characteristic curves analyses. Results: In this study, a median HER2/CEP17 ratio of 6.11 (95% CI, 2.27 to 21.90) and a median HER2 gene copy number of 11.90 (95% CI, 3.30 to 43.80) were found. A mean HER2/CEP17 ratio of 4.7 was identified as the optimal cutoff value discriminating sensitive and refractory patients (P = .005). Similarly, the optimal cutoff for predicting survival longer than 12 months was 4.45 (P = .005), and for survival longer than 16 months was 5.15 (P = .004). For HER2 GCN, the optimal cutoff values were 9.4, 10.0, and 9.5, respectively (P = .02). Conclusion: The level of HER2 gene amplification significantly predicts sensitivity to therapy and overall survival in advanced gastric cancer treated with trastuzumab-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171
Cited by
Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.48 · Cited by 1,012
Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., Mansoor, W., Chung, H. C., Bodoky, G., Shitara, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30111-0 · Cited by 547
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Janjigian, Y. Y., Sanchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., Riches, J. C., Tuvy, Y., Kundra, R., Bouvier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0787 · Cited by 375
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30169-8 · Cited by 362
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 350
Self-citation
Metadata
- Authors
- Gomez-Martin, C., Plaza, J. C., Pazo-Cid, R., Salud, A., Pons, F., Fonseca, P., Leon, A., Alsina, M., Visa, L., Rivera, F., Galan, M. C., del Valle, E., Vilardell, F., Iglesias, M., Fernandez, S., Landolfi, S., Cuatrecasas, M., Mayorga, M., Jose Paulés, M., Sanz-Moncasi, P., Montagut, C., Garralda, E., Rojo, F., Hidalgo, M., & Lopez-Rios, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-12-10
- Volume
- 31
- Issue
- 35
- Pages
- 4445-4452
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171136968
- Cited by
- 189
- References
- 4
- FWCI
- 15.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. https://app.cochat.ai/papers/10.1200/jco.2013.48.9070
- The paper
- Gomez-Martin, C., Plaza, J. C., Pazo-Cid, R., Salud, A., Pons, F., Fonseca, P., Leon, A., Alsina, M., Visa, L., Rivera, F., Galan, M. C., del Valle, E., Vilardell, F., Iglesias, M., Fernandez, S., Landolfi, S., Cuatrecasas, M., Mayorga, M., Jose Paulés, M., . . . Lopez-Rios, F. (2013). Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.48.9070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.